Publications

Jhatakia A, Sun X, Vaccaro A, Wang M, Nasser M, Mukhopadhyay A, Gupta N, Kang K, Hu W, Newsome C, Leung CH, Le J, Yazdani M, Guo H, Chen L, Pradhan M, Lin HY, Mandawe R, Findeisen F, Lohre J, Leung L, Wei Y, Dobroff J, O'Brien S, Xu K, Hammell A, Price K, Engelhardt J, Selby M, Korman A, Wilson N, Cascone T. Improving anti-CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies. Clin Cancer Res. 2026 Mar 16. doi: 10.1158/1078-0432.CCR-25-1230. Online ahead of print. PMID: 41837748

Remon J, Cascone T, Peters S. BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Jan 22:JCO2502696. PMID: 41570254

Provencio M, Awad MM, Spicer JD, Janssens A, Moiseyenko F, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N,Franke F, Hiltermann TJN, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T. Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: Phase 3CheckMate 77T exploratory analysis. Nat Cancer Nat Cancer. 2026 Jan;7(1):169-181. PMID: 41507539. 

Spicer JD*, Peters S* , Gainor JF, Chaft JE, Bestvina CM, Lee JM, Marron TU, Khattak MA, Ojalvo LS, Banerjee JK, Wang Z,  Deng X, Shariati N, Keller SM, Cascone T. Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non‒Small-Cell Lung Cancer. Ann Thorac Surg Short Reports, 2026, in press.

Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers(Basel). 2025 Nov 27;17(23):3801. PMID: 41375002

Peng F, Sinjab A, Dai Y, Treekitkarnmongkol W, Yang S, Gomez Bolanos LI, Zhou T, Chen M, Serrano AG, Krishna A, Karimi N, Sharma M, Basi A, Pei G, Liao J, Liu Y, Feng J, Rahal Z, Liu Y, Jiang J, Yu K, Noun T, Liu Y, Khan K, Cho KS, Chen J, Solis LM, Mazzilli S, Dubinett S, Cascone T, Spira AE, Swisher S, Jimbo N, Hayashi T, Kishikawa S, Takamochi K, Itoh T, Yao T, Suzuki K, Kalhor N, Wistuba II, Li M, Moghaddam SJ, Fujimoto J, Burks J, Myers J, Akdemir K, Wang L, Kadara H. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer Cell. 2025 Nov 6:S1535-6108(25)00445-3. PMID: 41202811

Salehjahromi M, Li H, Showkatian E, Saad MB, Qayati M, Ismail SM, Sujit SJ, Muneer A, Aminu M, Hong L, Han X, Heeke S, Cascone T, Le X, Vokes N, Gibbons DL, Toumazis I, Ostrin EJ, Antonoff MB, Vaporciyan AA, Jaffray D, Kay FU, Carter BW,Wu CC, Godoy MCB, Lee JJ, Gerber DE, Heymach JV, Zhang J, Wu J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers (Basel). 2025 Oct 23;17(21):3406. PMID: 41228201

Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol. 2025 Oct;9:e2500538. PMID: 41166675

Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson MB, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nat Cell Biol. 2025 Oct 13. PMID:41083603

Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q; RTI Team; Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nat Commun. 2025 Sep 26;16(1):8499. PMID: 41006245

Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X,Elamin Y, Altan M, Heeke S, Sheshadri A, Chang J, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili , Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun. 2025 Jul24;16(1):6828. PMID: 40707438

Awada G, Cascone T, van der Heijden M, Blank C, Chalabi M. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types. Nat Cancer. 2025 Jun;6(6):967-987. doi: 10.1038/s43018-025-00990-7. Epub 2025Jun 24. PMID: 40555863

Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer. 2025 Jun 24;13(6):e011458. doi: 10.1136/jitc-2025-011458. PMID:40555561

Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L, Egenod T, Corre R, Kim DW, Garcia Campelo MR, Provencio Pulla M, Shim BY, Metro G, Bennouna J, Bielska AA, Yohannes AR, He Y, Dowson A, Kar G, McGrath L, Kumar R, Grenga I, Spicer J, Forde PM. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform Phase 2 NeoCOAST-2 trial. Nat Med. 2025 May 31 PMID: 40450142

Rahal, Z, El Darzi, R, Moghaddam, SJ, Cascone T, Kadara H. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol. 2025 May 16. PMID: 40379986

Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep. 2025 Jan 6;6(4):100795. eCollection 2025 Apr. PMID: 40160974

Vaccaro A, Rahal Z, Kadara H, Cascone T. A Roadmap to Precision Immunotherapy for Early-Stage Non-Small Cell Lung Cancer. Cancer Discov. 2025 Feb 25:OF1-OF6. PMID: 39997992

Cascone T, William WN Jr. Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer. Nat Rev Clin Oncol. 2025 Feb;22(2):81-82.PMID: 39627503

Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A,Peters S, Remon J. Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. Cancer Treat Rev. 2025 Feb 16;134:102902. PMID: 39978083

Lermi NO, Ayala MM, Ruiz SH, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q; RTI Team; Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. Res Sq [Preprint].2025 Jan 17:rs.3.rs-5656204. PMID: 39877088

Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J,Liang Q, Team R, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. bioRxiv [Preprint]. 2024 Dec 17:2024.12.13.628390. PMID: 39763763

Sujit S, Aminu M, Karpinets T, Chen P, Saad M, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes N, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens MC, Godoy M, Wu CC, Chang JY, Chung C, Jaffray D, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nature Commun. 2024 Dec 01; 15(1) PMID: 38605064

Spicer JD, Cascone T, Wynes MW, Kelly KL. Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy? J Thorac Oncol. 2024 Dec; 19(12):e98-e99. PMID: 39645317

Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KK, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review. J Thorac Oncol. 2024 Nov 30; PMID: 39622411

Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL,Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10) PMID: 39448200

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y,Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F,Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B,Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J,Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S,Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Oct 09; PMID: 39385035

Pan K, Owens J, Elamin YY, Lu C, Routbort MJ, Zhang J, Fossella FV, Vailati Negrao M, Altan M, Pozadzides JV, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin EJ, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct 01; 19(10):1438-1448. PMID: 38866326

Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. Neoadjuvant and Adjuvant Treatments for Early-Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024 Oct; 19(10):1373-1414. PMID: 38901648

Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, ChenM, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B,Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K,Kadara H. Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment. Cancer Immunol Res. 2024 Sep 13; PMID: 39269772

Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E. Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist. 2024 Sep 05; PMID: 39237103

Cascone T, Spicer JD, Provencio Pulla M. Perioperative Nivolumab in Resectable Lung Cancer. Reply. N Engl J Med.2024 Aug 08; 391(6):573-574. PMID: 39115074

Hines, J, Cameron, RB, Esposito, A, Kim, L, Porcu, L, Nuccio, A, Viscardi, G, Ferrara, R, Veronesi, G, Forde, PM, Taube, JM,Vokes, EE, Bestvina, CM, Dolezal, JM, Sacco, M, Monteforte, M, Cascone, T, Garassino, MC, Torri, V. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul 01; 19(7):1108-1116. PMID: 38461929

Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka L, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseenko F, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16; 390(19):1756-1769. PMID: 38749033

Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, Crump T, Walsh LA, Fiset PO, Sepesi B, Forde PM, Cascone T, Provencio M, Spicer JD. Neoadjuvant Chemoimmunotherapy for NSCLC. JAMA Oncol. 2024 May 16; 10(5):621-633. PMID: 38512301

Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen Q, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiotherapy andOncology. 2024 Apr 01; 193 PMID: 38311031

Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano A, Feng J, Liang K, Khan KB, Lu W, Hernandez S, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez Bolanos L, Peng F, Chen M, Parra Cuentas ER, Cascone T, Sepesi B, Moghaddam SM, Scheet PA, Vailati Negrao M, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis Soto LM, Wistuba II, Chen J, Wang L, Kadara HN. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Mar 21; 627(8004):656-663. PMID: 38418883

Salehjahromi M, Karpinets T, Sujit S, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes N, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy M, Chung C, Jaffray D, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine. 2024 Mar 19; 5(3) PMID: 38471502

Khushalani N, Ott PA, Ferris R, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman WH, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH. Final results ofurelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. J Immunother Cancer. 2024 Mar 07; 12(3) PMID: 38458639.

Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 Dec; 195:113404. PMID: 37948842

Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, VaporciyanAA, Heymach JV, Zhang J, Le X. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. ePub 2023 Nov; PMID: 38012986

Sepesi B, Mehran R, Spicer J, Cascone T. NEOSTAR trial and the current status of neoadjuvant therapy in non-small cell lung cancer. J Thorac Cardiovasc Surg. ePub 2023 Nov; PMID: 37923289

Tran HT, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, Lam VK, Vaporciyan A, Swisher SG, Godoy MCB, Cascone T, SepesiB, Gibbons DL, Wu J, Heymach JV. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer. Ann Oncol. ePub 2023 Nov; PMID: 37992871

Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, Cascone T, Lee JJ, Pataer A. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol. ePub 2023 Oct; 37(1):100353. PMID:37844869

Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN Jr, Walsh GL, Rice DC, Roth JA, Reza Md J M, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg. 2023 Oct 8:S0022-5223(23)00900-5. doi: 10.1016/j.jtcvs.2023.09.073. Online ahead of print. PMID: 37816395

Cascone T, Kar G, Spicer JD, García-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436.PMID: 37707791 Clinical Trial.

Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA Jr, Kris MG, Belani CP, Kelly K, Wistuba I; IASLC Pathology Committee. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023 Oct;18(10):1290-1302. doi: 10.1016/j.jtho.2023.07.017. Epub 2023 Sep 12. PMID: 37702631

Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 Sep 9;402(10405):871-881. doi: 10.1016/S0140-6736(23)01384-3. Epub 2023 Jul 18. PMID: 37478883 Clinical Trial.

Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 Mar;29(3):593-604. doi: 10.1038/s41591-022-02189-0. Epub 2023 Mar 16. PMID: 36928818. Clinical Trial.

Deboever N, McGrail DJ, Lee Y, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Bernatchez C, Vailati Negrao M, Zhang J, Wistuba II, Heymach JV, Cascone T, Gibbons DL, Haymaker CL, Sepesi B. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 Feb;164:69-75. Epub 2022 Jan 8. PMID: 35038676.

Sepesi B*, Zhou N, William Jr. WN, Lin HY, Leung C, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T*. Surgical Outcomes Following Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg. January 2022, PMID: 35190177. *Co-leading authors.

Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 Feb;10(2):e003082. PMID: 35110355.

Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current Surgical Indications for Non-Small-Cell Lung Cancer. Cancers (Basel). 2022 Feb 28;14(5):1263. PMID: 35267572

Cascone T, Chelvanambi M, Wargo JA. Immunotherapy response-associated Akkermansia: canary in a coal mine? Trends Immunol. 2022 May;43(5):337-339. PubMed PMID: 35397955.

Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 Apr 12;13(1):1970. PMID: 35413951.

Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridion B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Clin Cancer Res. 2022 Apr 8. PMID: 35394499.

Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1-2, 2021. J Transl Med. 2022 Jun 15;20(1):271. PMID: 35706041.

Mittendorf EA*, Burgers F, Haanen J, Cascone T*. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15. PMID: 35714302. *Equal Contribution.

Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan AA, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV,  Gibbons, DL, and the ICON team. A shared nearest neighbors approach and interactive browser for network analysis of a comprehensive non-small cell lung cancer dataset. JCO Clin Cancer Informatics, 6/30/2022, In press.

Elamin YY, Robichaux JP, Carter B, Altan M, Tran HT, Gibbons DL, Fossella FV, Lam VK, Le X, Negrao, MV, Nilsson MN, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity. Cancer Cell, 2022 Jul 11;40(7):754-767.e6.

Hao D, Han G, Sinjab A, Gomez-Bolanos L, Lazcano R, Serrano, Hernandez S, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra E, Wargo J, Swisher S, Cascone T, Sepesi B, Futreal A, Li M, Dubinett S, Fujimoto J, Solis Soto L, Wistuba II, Stevenson C, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov 7/20/2022. In press.

Patel S, Nilsson M, Le X, Cascone T, Jain R, Heymach JV. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res 7/21/2022, In press.

Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 1/2021. PMCID: PMC7781147.

Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T*. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res 10(1):590-606, 1/2021. PMCID: PMC7867746. *Corresponding author.

Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra- Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 1/2021. PMCID: PMC7775914.

Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg 59(1):100-108, 1/2021. PMID: 32864702.

Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol 16(3):439-451, 3/2021. PMCID: PMC8207565.

Cascone T*, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 3/2021. PMID: 33603241. *Corresponding author (Selected for the Wall of Science and Research Excellence in Science, MD Anderson Cancer Center).

Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 Jun;32(6):817-819. Epub 2021 Feb 20. PMID: 33617938.

Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. e-Pub 4/2021. PMID: 33911215.

Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6), 3/2021. PMCID: PMC7998226.

Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer 154:76-83, 4/2021. e-Pub 2/2021. PMID: 33631448.

Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T, Swisher SG. Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. e-Pub 4/2021. PMID: 33857666.

Sepesi B, Cascone T. Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer? Lancet Oncol 22(6):744-746, 6/2021. PMID: 34015310.

Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. e-Pub 5/2021. PMID: 33972311.

Cascone T*, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V*. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open. 2021 Apr;6(2):100079. *Co-corresponding author.

Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 2021 70(7):1977-1978. PMCID: PMC8195756. 

Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer. J Thorac Oncol. 2021 Jul 23:S1556-0864(21)02320-0. PMID: 34311109.

Cascone T*, Fradette J, Pradhan M, Gibbons DL. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harb Perspect Med. 2021 Sep 27:a037895. PMID: 34580079. *Co-corresponding author.

Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, Bourdon JC, Johnson FM, Heymach JV. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. J Biol Chem. 2021 Sep 2:101163. PMID: 34481841.

Cascone T*, Weissferdt A, Godoy MCB, William WN Jr, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 Aug 19;12(1):5045. PMID: 34413300. *Co-corresponding author.

Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 Aug;9(8):e002891. PMID: 34376553.

Shu CA*, Cascone T*. What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Sep 10;39(26):2855-2858. PMID: 34339287. *Equal contribution.

Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 2021 Oct 12;S0923-7534(21)04519-1. PMID: 34653632.

Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 1/2020. PMCID: PMC6992630.

Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg 109(2):358-366, 2/2020. PMCID: PMC7366360.

Sepesi B, Cascone T. Commentary: Neoadjuvant checkpoint inhibitors in resectable non-small cell lung cancer-Ready for prime time? J Thorac Cardiovasc Surg 159(4):1624-1625, 4/2020. PMID: 31648835.

Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 4/2020. PMCID: PMC7213906.

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary recommendations for pathological assessment of lung cancer resection specimens following neoadjuvant therapy. J Thorac Oncol 15(5):709-740, 5/2020. PMID: 32004713.

Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 7/2020. PMID: 32193228. (Selected for Journal Cover).

Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer 21(4):341-348, 7/2020. PMCID: PMC7305995.

Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi B. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer 21(4):e294-e301, 7/2020. PMID: 32089476.

Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W*, Cascone T*. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 8/2020. PMID: 32300858. *Co-corresponding author.

Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 8/2020. PMID: 32619781.

Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 9/2020. PMID: 32389639.

Sepesi B, Cascone T, Chun SG, Altan M, Le X. Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. Surg Oncol Clin N Am 29(4):555-569, 10/2020. PMCID: PMC7388816.

Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist 24(6):772-782, 6/2019. PMCID: PMC6656515.

Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(2):418-424, 2/2018. PMCID: PMC5783769.

Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 5/2018. PMCID: PMC5932208.

Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 6/2018. PMCID: PMC5989476.

Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 6/2018. PMID: 29410488.

Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov 8(9):1156-1175, 9/2018. PMID: 30012853.